Sage Journals: Discover world-class research

Abstract

Background

To compare the hemodynamic and biological effects of high-adsorption continuous veno-venous hemofiltration (CVVH) with standard CVVH in septic shock. Methods: In a randomized cross-over clinical trial twelve patients with septic shock and multiple organ failure were enrolled at a tertiary intensive care unit. Patients were allocated to either 9 hours of high-adsorption hemofiltration (CVVH with 3 hourly filter change using AN69 hemofilters - 3F-CVVH) or 9 hours of standard hemofiltration (CVVH without filter change - 1F-CVVH).

Results

Changes in hemodynamic variables, dose of noradrenaline required to maintain a mean arterial pressure greater than 75 mmHg and plasma concentrations of cytokines (IL-6, IL-8, IL-10 and IL-18) were measured. A 9-hour period of 3F-CVVH was associated with greater reduction in noradrenaline dose than a similar period of 1F-CVVH (median reduction: 16 vs. 3.5 μg/min, p=0.036; median percentage reduction: 48.1% vs. 17.5%, p=0.028). Unlike 1F-CVVH, 3F-CVVH was associated with a reduction in the plasma concentration of IL-6, IL-10 and IL-18 at 9 hours and a significant decrease 30 minutes after additional filter changes (IL-6: p<0.01, p<0.01; IL-10: p=0.03, p=0.016 and IL-18: p=0.016, p<0.01, respectively). Both, 3F-CVVH and 1F-CVVH were associated with decreased plasma concentrations of IL-8 at 9 hours (p<0.01, p<0.01, respectively). In a confirmatory ex-vivo experiment IL-6 concentrations substantially decreased during 3F-CVVH (at baseline 511pg/mL and at end: 21pg/mL) whereas IL-6 concentrations increased in control blood (at baseline 511pg/mL and at end: 932pg/mL).

Conclusions

High-adsorption CVVH appears more effective than standard CVVH in decreasing noradrenaline requirements and plasma concentrations of cytokines in septic shock patients.

Keywords

Cytokines Hemofiltration Septic shock Interleukin-6 Interleukin-10 Multiorgan failure

Get full access to this article

View all access options for this article.

References

Tetta

, Mariano

, Ronco

. Removal and generation of inflammatory mediators during continuous renal replacement therapies. Crit Care Nephrol 1998; 1239–48.

Manns

, Sigler

M.H.

, Teehan

B.P.

Continuous renal replacement therapies: An update.

Am J Kidney Dis 1998; 32: 185–207.

Schetz

Classical and alternative indications for CRRT.

Kidney Int 1998; 53(suppl 66): 129–32.

Rogiers

, Zhang

, Pauwels

. Comparison of polyacrylonitrile (AN69) and polysulphone membrane during hemofiltration in canine endotoxic shock. Crit Care Med 2003; 31: 1219–25.

Kellum

J.A.

, Dishart

M.K.

Effect of hemofiltration filter adsorption on circulating IL-6 levels in septic rats.

Crit Care 2002; 6: 429–33.

De Vriese

A.S.

, Colardyn

F.A.

, Philippe

J.J.

. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999; 10: 846–53.

Bone

R.C.

, Balk

R.A.

, Cerra

F.B.

. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644–55.

Cole

, Bellomo

, Journois

. High-volume haemofiltration in human septic shock. Intensive Care Med 2001; 27: 978–86.

Heering

, Morgera

, Schmitz

F.J.

. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 1997; 23: 288–96.

10.

Sanchez-Izquierdo

J.A.

, Perez Vela

J.L.

, Lozano Quintana

M.J.

. Cytokines clearance during veno-venous hemofiltration in the trauma patient. Am J Kidney Dis 1997; 30: 483–8.

11.

Grootendorst

A.F.

, van Bommel

E.F.

The role of hemofiltration in the critically-ill intensive care unit patient: Present and future.

Blood Purif 1993; 11: 209–23.

12.

Gasche

, Pascual

, Suter

P.M.

. Complement depletion during haemofiltration with polyacrilonitrile membranes. Nephrol Dial Transplant 1996; 11: 117–9.

13.

Cole

, Bellomo

, Hart

. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30: 100–6.

14.

Marie

, Losser

M.R.

, Fitting

. Cytokines and soluble cytokine receptors in pleural effusions from septic and nonseptic patients. Am J Respir Crit Care Med 1997; 156: 1515–22.

15.

Cavaillon

J.M.

, Munoz

, Fitting

. Circulating cytokines: The tip of the iceberg? Circ Shock 1992; 38: 145–52.

16.

Sieberth

H.G.

, Kierdorf

H.P.

Is cytokine removal by continuous hemofiltration feasible?

Kidney Int 1999; 72(suppl): S79–83.

17.

Webb

L.M.C.

, Ehrengruber

M.U.

, Clark-Lewis

. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci 1993; 90: 7158–62.

18.

Morgera

, Haase

, Kuss

. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006; 34: 2099–104.

19.

van Kuijk

W.H.

, Hillion

, Savoiu

. Critical role of the extracorporeal blood temperature in the hemodynamic response during hemofiltration. J Am Soc Nephrol 1997; 8: 949–55.

20.

Morgera

, Slowinski

, Melzer

. Renal replacement therapy with high cut-off hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 2004; 43: 444–53.

A Pilot Study of High-Adsorption Hemofiltration in Human Septic Shock